BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Docetaxel: trial readouts and FDA decisions
17 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 15 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sichuan Baili Pharmaceutical Co., Ltd., Akeso, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Merck Sharp & Dohme LLC, Shanghai JMT-Bio Inc., Amgen, Jiangsu HengRui Medicine Co., Ltd., Nanjing Leads Biolabs Co.,Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-11-30 est. | P1/P2 | Amgen AMGN | NCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | active not recruiting | 329 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | Head and Neck Squamous Cell Carcinoma | active not recruiting | 45 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | Non-small Cell Lung Cancer | active not recruiting | 698 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | Prostate Cancer | recruiting | 100 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12-16 est. | P3 | Shanghai JMT-Bio Inc. | NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | Early or Locally Advanced HER2-positive Breast Cancer | active not recruiting | 520 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-25 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06525350 A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed | Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpressio | not yet recruiting | 256 |
| 2026-12-30 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | Selected Subjects With Advanced Solid Tumors | active not recruiting | 321 |
| 2026-12-30 est. | P3 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | recruiting | 490 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 594 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01 est. | P1/P2 | iOnctura | NCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC | active not recruiting | 45 |
| 2027-02 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cance | recruiting | 250 |
| 2027-02 est. | P2 | Genelux Corporation GNLX | NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; M | recruiting | 142 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Nasopharyngeal Carcinoma | active not recruiting | 386 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-10 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy | Non Small Cell Lung Cancer | recruiting | 522 |
| 2026-09-03 | P3 | Novartis Pharmaceuticals NVS | NCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | terminated | 95 |
| 2026-09 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced So | Solid Tumor | not yet recruiting | 240 |
| 2026-07-15 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT07116824 HB1801 Combined Treatment of HER2-positive Breast Cancer | HER2-positive Breast Cancer | not yet recruiting | 80 |
| 2026-07-03 est. | P3 | Boehringer Ingelheim | NCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS) | withdrawn | |
| 2026-07-01 est. | P2/P3 | Shanghai JMT-Bio Inc. | NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer | Squamous Cell Non-small Cell Lung Cancer | not yet recruiting | 534 |
| 2026-07 est. | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | recruiting | 402 |
| 2026-07 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung | active not recruiting | 589 |
| 2026-07 est. | P2 | Akeso | NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 265 |
| 2026-06-30 est. | P1/P2 | Akeso | NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 233 |
| 2026-06-17 | P3 | Hansoh BioMedical R&D Company | NCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Osteosarcoma | completed | 122 |
| 2026-06-01 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06296706 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | Gastric Cancer | recruiting | 630 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.